<DOC>
	<DOCNO>NCT00001761</DOCNO>
	<brief_summary>The purpose study assess safety , tolerance , immunologic effect interleukin-10 ( IL-10 ) , patient Wegener 's granulomatosis . A secondary objective determine IL-10 demonstrate sufficient anti-inflammatory activity treatment Wegener 's granulomatosis warrant study large trial . In study , IL-10 give either alone combination standard therapeutic agent , usually consist cyclophosphamide , methotrexate , and/or prednisone . Patients eligible receive IL-10 evidence active disease . IL-10 administer subcutaneous injection dose 4 µ ( Micro ) g/kg/day 28 day .</brief_summary>
	<brief_title>Phase I Trial Recombinant Human Interleukin-10 ( SCH 52000 ) Patients With Wegener 's Granulomatosis</brief_title>
	<detailed_description>The purpose study assess safety , tolerance , immunologic effect interleukin-10 ( IL-10 ) , patient Wegener 's granulomatosis . A secondary objective determine IL-10 demonstrate sufficient anti-inflammatory activity treatment Wegener 's granulomatosis warrant study large trial . In study , IL-10 give either alone combination standard therapeutic agent , usually consist cyclophosphamide , methotrexate , and/or prednisone . Patients eligible receive IL-10 evidence active disease . IL-10 administer subcutaneous injection dose 4 µ ( Micro ) g/kg/day 28 day .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis Polyangiitis</mesh_term>
	<criteria>Diagnosis Wegener 's granulomatosis base clinical characteristic histopathological and/or angiographic evidence vasculitis presence glomerulonephritis positive assay antineutrophil cytoplasmic autoantibody ( ANCA ) . Age 18 65 year . No change immunosuppressive drug therapy prior 4 week one following : Persistent disease activity ( `` Vasculitis Activity Index '' score great equal 3 ) despite optimal therapy ; Persistent recurrent disease activity patient tolerate optimal therapy ; Patients maximal immunosuppressive therapy persistent recurrent disease activity , judgment investigator , immediately threaten function major organ system ; No evidence active infection . Patients may pregnant nursing infant . Fertile woman must negative pregnancy test within one week prior study entry participant must use effective mean birth control . Serum creatinine le 3.5 mg/dL . Hemocytopenia ( platelet count great 100,000/mm ( 3 ) , leukocyte count great 3,500/mm ( ) , hemoglobin great 9 mg/dL ) . Liver function test abnormalities less 3x upper limit normal ( either serum GOT , GPT , alkaline phosphatase , and/or bilirubin ) . Patients antiHIV , antiHCV , antiHepatitis B surface antigen ( HBsAG ) positive . Weight great less 104 Kg ( SCH 52000 concentration volume limitation subcutaneous injection ) . No treatment investigational drug within 30 day . No preexisting malignancy . No known allergy E. coli protein IL10 . No history psychiatric illness opinion principal investigator would preclude entrance study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1999</verification_date>
	<keyword>Autoimmunity</keyword>
	<keyword>Cytokine</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Interleukin</keyword>
	<keyword>Vasculitis</keyword>
	<keyword>Wegener 's Granulomatosis</keyword>
</DOC>